Factor XI deficiencies are rare. Initially, they were described only in Ashkenazy Jews with two types of characteristic gene mutation. Now, 152 mutations have been identified, mostly in non-Jewish population.
Introduction
Factor XI (FXI) deficiency was originally described in a Jewish family in the USA and was called "hemophilia C" and distinguish from hemophilia A or B by its occurrence in either sex and the absence of spontaneous bleeding [1] .
FXI deficiency is particularly common in Ashkenazi Jews; it is one of the most common genetic disorders in this population with heterozygous frequency of 8% [2] . The frequency of FXI deficiency in non-Jewish people is unknown, as is the case for Algeria. This bleeding disorder is probably underdiagnosed because patients with severe or partial FXI deficiency do not suffer from spontaneous bleeding but may do so only after haemostatic challenge, generally related to surgery or trauma. In particular, women's are exposed to a haemostatic challenge every month during their menstrual period.
The other common challenge for women is childbirth. Moreover, there is often a poor correlation between bleeding and the baseline FXI clotting activity [3] . Inherited FXI deficiency has now been described in a wide variety of population groups but remains most common in Ashkenazy Jews. In this group, it is estimated that one in eight individuals is heterozygous and one in 190 homozygous for mutations in the FXI gene [4, 5] .
Most cases of FXI deficiency in Ashkenazi Jews are caused by two distinct mutations, each accounting for 40-50% of abnormal alleles. These are Glu117Strop referred to as the type II mutation and Phe283Leu, the type III mutation.
The type III mutation occurs almost exclusively in Ashkenazy Jews, but the type II mutation is also found in Iraqi Jews and Arabs, suggesting an earlier ancestral origin [6, 7] . Phe283Leu results in impaired dimer formation producing a quantitative deficiency [8] . We report the case of factor XI deficiency discovered in a little girl born in Mostaganem, Western Algerian city.
Materials and Methods
Patient B.K was born in 1997 in Mostaganem; she was referred in haematology in 2008 for exploration of a PTT discovered during preoperative assessment for tonsillectomy. Clinical examination was normal, but medical history was marqued by frequent epistaxis, hematomas after intramuscular injections and ecchymosis. Mennarchies occurs at 11 years old and were very important. Her parents are cousins and she is the youngest of 3 brothers and 3 sisters; no one of them presents any bleeding symptom, and they refuse to be included in screening.
Coagulation assays
Blood was obtained from the patient, her father and mother after informed consent.
Prothrombin time, a PTT fibrinogen concentration, factor VIII, factor IX and factor XI activities and von Willebrand factor (ristocetin co-factor activity and antigen) were measured with standard assays using the BCS analyser (Dade Behring, Marburg, Germany) and the Vidas analyser (BioMerieux, Marcy l'Etoile, France).
Molecular analyses
Genomic DNA from the proband, the father and the mother was purified from leucocytes according to standard protocols. The F11 gene was analysed by direct sequencing. 
Results

Coagulation results for the propositus
Discussion
In the literature, we found no other cases of FXI deficits reported in Algeria; this is abnormal because our country's history is marqued by significant migratory currents of Turkish , Spanish and French people; moreover, after the conquest of Granada by the Catholic in 1492, many Sephardic Jews setted and lived for long time in Algeria, and the consanguine marriages are still frequent.
But we now that FXI deficiency is a rare bleeding disorder that occurs in general population at frequency of one in a million [9] ; may be that is the reason why patients do not consult.
As reported [10] , FXI deficiency is associated with a variable injuryrelated bleeding diathesis in most severely deficient patients and in 50% of partially deficient patients. Bleeding is associated with trauma or surgery, and spontaneous bleeding is not typical. This is the case in our patient; despite a severe deficiency, haemorrhagic signs remains moderate. Several studies have been conducted to evaluate the determinants of bleeding tendency and neither plasma levels of FXI coagulant activity (FXI:C) nor FXI antigen (FXI:Ag) were associated with bleeding. However, bleeding is significantly associated with homozygous type II mutations and compound type II-type III mutations in FXI, resulting in severe deficiency in FXI and low plasma levels. Bleeding is also increased when plasma levels of the von Willebrand factor (VWF) are at the lower end of normal levels [11] .
Over 96% of FXI deficiency is accounted for by two of four common mutations found in Ashkenazi Jews, namely type II (a nonsense mutation in exon 5) and type III (a missense mutation in exon 9) [12] .
Yssufumi Manaka and coll. Identified two other mutations in non-Jewish population, in case 1, a T to G transition in exon 12 results in the substitution of Phe-442 by Val (FXLF442V); in case 2 a C to A transition in exon 5 results in the substitution of Cys-128 by a nonsense codon (FXI-C128X) [13] . Anwar Alhaq and colleagues described another mutation in non-Jewish population, TGG to TGC transversion in codon 228 of exon 7 (FXI-W228C). This missense mutation results in a Trp to Cys substitution within the third apple domain of FXI [14] .
In France, nine others mutations were identified in seven families from the west of France [15] : Q88X het (exon 4), Q88X hom (exon 4), T575M het (exon 15), nt 137 ins G (exon 3), R210X het (exon7), G336R het (exon 10), G581X hom (exon 15), G581X het (exon15) and G350A het (exon 10). Curiously, all these mutations have no different clinical consequences.
To date, 152 mutations in the FXI gene have been reported with four exhibiting founder effects in specific populations, Glu117stop in Ashkenazi and Iraqui Jews and Arabs, Phe283Leu in Ashkenazi Jews, Cys38Arg in Basques, and Cys128stop in the United Kingdom Severe FXI deficiency does not confer protection against acute myocardial infarction, but is associated with reduced incidence of ischemic stroke. Inhibitors to FXI develop in one-third of patients with very severe FXI deficiency following exposure to blood products. Therapy for prevention of bleeding during surgery in patients with severe FXI deficiency consists of plasma, factor XI concentrates, fibrin glue and anti-fibrinolytic agents. In patients with an inhibitor to FXI, recombinant factor VIIa is useful [16] .
Concerning Algeria, we think that this case report is the first one published; we hope that it will be not the last; we have to prospect about frequency of FXI deficiency and types of mutations associated, and we are discussing with researchers of the anthropology center for more information about the history of migration in Algeria.
